Association of Accessible Medicines (Formerly Known as Gpha)
Trade Organization for Generic Drug Manufacturers and Distributers
Based in DC
🤖
AI Overview
With $1.7M in lobbying spend across 30 quarterly filings, Association of Accessible Medicines (Formerly Known as Gpha) is a significant lobbying presence.
$1.7M
Total Lobbying Spend
30
Quarterly Filings
1
Lobbying Firms Used
10
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $180K |
| 2019 | $180K |
| 2020 | $220K |
| 2021 | $220K |
| 2022 | $240K |
| 2023 | $200K |
| 2024 | $230K |
| 2025 | $240K |
Lobbying Firms
FIERCE GOVERNMENT RELATIONS
What They Lobby For
- Issues relating to generic drug competition, drug pricing, S. 974 - CREATES Act of 2017, H.R.2212 - CREATES Act of 2017, S. 2514- PACED Act
- Issues relating to generic drug competition, drug pricing, S. 974 - CREATES Act of 2017, H.R.2212 - CREATES Act of 2017, Hatch Waxman Integrity Act
- USMCA/NAFTA
- Issues relating to generic drugs, drug pricing, S. 974 - CREATES Act of 2017, H.R.2212 - CREATES Act of 2017, Hatch Waxman Integrity Act
- Issues relating to generic drugs, drug pricing, S. 340 - CREATES Act of 2019, Patent Abuse, S. 64- Preserve Access to Affordable Generics and Biosimilars Act, S. 1895- Lower Health Care Costs Act- Sec. 205, H.R. 965- CREATES Act of 2019
- Issues relating to generic drugs, drug pricing, S. 340 - CREATES Act of 2019, S. 64- Preserve Access to Affordable Generics and Biosimilars Act, S. 1895- Lower Health Care Costs Act- Sec. 205, H.R. 965- CREATES Act of 2019, S. 1416- Affordable Prescriptions for Patients Act of 2019, S. 2543 - Prescription Drug Pricing Reduction Act of 2019
- Issues relating to generic drugs, drug pricing, S. 340 - CREATES Act of 2019, S. 64- Preserve Access to Affordable Generics and Biosimilars Act, S. 1895- Lower Health Care Costs Act- Sec. 205, H.R. 965- CREATES Act of 2019, S. 1416- Affordable Prescriptions for Patients Act of 2019, S. 2543 - Prescription Drug Pricing Reduction Act of 2019, H.R. 1865- Further Consolidated Appropriations Act, 2020
- Drug pricing, S. 1895- Lower Health Care Costs Act- Sec. 205, S. 2543 - Prescription Drug Pricing Reduction Act of 2019, H.R. 748- CARES Act, Supply Chain
- Supply Chain, S. 4049- National Defense Authorization Act, House China Task Force
- Supply Chain, Executive Order 13944- Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.